Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
DiaMedica Therapeutics Inc is a biotechnology business based in the US. DiaMedica Therapeutics shares (DMAC) are listed on the NASDAQ and all prices are listed in US Dollars. DiaMedica Therapeutics employs 10 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $2.41 |
|---|---|
| 52-week range | $2.20 - $10.88 |
| 50-day moving average | $3.61 |
| 200-day moving average | $5.02 |
| Wall St. target price | $18.20 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.77 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.41 from 2022-01-26
| 1 week (2022-01-21) | -9.06% |
|---|---|
| 1 month (2021-12-28) | -30.14% |
| 3 months (2021-10-28) | -39.75% |
| 6 months (2021-07-28) | -30.55% |
| 1 year (2021-01-28) | -68.94% |
|---|---|
| 2 years (2020-01-28) | -41.93% |
| 3 years (2019-01-28) | 3.7499 |
| 5 years (2017-01-25) | 1,959.83% |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -22.94% |
| Return on equity TTM | -37.88% |
| Profit margin | 0% |
| Book value | $1.78 |
| Market capitalisation | $63.7 million |
TTM: trailing 12 months
We're not expecting DiaMedica Therapeutics to pay a dividend over the next 12 months.
DiaMedica Therapeutics's shares were split on a 1:20 basis on 14 November 2018. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your DiaMedica Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for DiaMedica Therapeutics shares which in turn could have impacted DiaMedica Therapeutics's share price.
Over the last 12 months, DiaMedica Therapeutics's shares have ranged in value from as little as $2.2 up to $10.88. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while DiaMedica Therapeutics's is 2.4065. This would suggest that DiaMedica Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
DiaMedica Therapeutics Inc. , a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc.
Five major factors contribute to the continued bull run of Bitcoin, ARK says, including growing adoption and long-term focus of investors.
Lido’s liquid staking allows investors holding LUNA and less than 32 ETH to reap the rewards of DeFi staking.
Downturns often let you buy fundamentally strong stocks at bargain prices, but mind the fundamentals and consider these 3 rules.
Walmart files trademarks with the goal to issue its own cryptocurrency and NFTs for use in its digital stores.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.